167 related articles for article (PubMed ID: 19536166)
1. Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: an analysis of the HYVET study from a Swiss perspective.
Szucs TD; Waeber B; Tomonaga Y
J Hum Hypertens; 2010 Feb; 24(2):117-23. PubMed ID: 19536166
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective.
Szucs TD; Burnier M; Erne P
Cardiovasc Drugs Ther; 2004 Sep; 18(5):391-7. PubMed ID: 15717142
[TBL] [Abstract][Full Text] [Related]
4. [New treatment strategies for the management of hypertension].
Reinhardt A; Linsel-Nitschke P; Schunkert H
MMW Fortschr Med; 2009 Nov; 151(46):33-6. PubMed ID: 20043391
[No Abstract] [Full Text] [Related]
5. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
[TBL] [Abstract][Full Text] [Related]
6. [Real and assumed potential savings in antihypertensive treatment. Right out of the magician's hat].
Anlauf M; Hense HW
Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1557-9. PubMed ID: 12854069
[No Abstract] [Full Text] [Related]
7. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
[TBL] [Abstract][Full Text] [Related]
9. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension.
Jönsson B; Hansson L; Stålhammar NO
J Intern Med; 2003 Apr; 253(4):472-80. PubMed ID: 12653877
[TBL] [Abstract][Full Text] [Related]
10. The value of antihypertensive drugs: a perspective on medical innovation.
Cutler DM; Long G; Berndt ER; Royer J; Fournier AA; Sasser A; Cremieux P
Health Aff (Millwood); 2007; 26(1):97-110. PubMed ID: 17211019
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacotherapy of hypertension. How much can safely be saved?].
Anlauf M
MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022
[No Abstract] [Full Text] [Related]
12. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
13. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
[TBL] [Abstract][Full Text] [Related]
14. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
[TBL] [Abstract][Full Text] [Related]
15. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Frei A; Palmer AJ; Burnier M; Hess B
Praxis (Bern 1994); 2006 Mar; 95(11):401-8. PubMed ID: 16570646
[TBL] [Abstract][Full Text] [Related]
16. A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
Anis AH; Sun H; Singh S; Woolcott J; Nosyk B; Brisson M
Pharmacoeconomics; 2006; 24(4):387-400. PubMed ID: 16605284
[TBL] [Abstract][Full Text] [Related]
17. Organized blood pressure control programs to prevent stroke in Australia: would they be cost-effective?
Cadilhac DA; Carter R; Thrift AG; Dewey HM
Stroke; 2012 May; 43(5):1370-5. PubMed ID: 22363058
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management.
Schultz BG; Tilton J; Jun J; Scott-Horton T; Quach D; Touchette DR
Value Health; 2021 Apr; 24(4):522-529. PubMed ID: 33840430
[TBL] [Abstract][Full Text] [Related]
19. A substudy protocol of the hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG) : An ongoing randomised, double-blind, placebo-controlled trial.
Peters R; Beckett N; Nunes M; Fletcher A; Forette F; Bulpitt C
Drugs Aging; 2006; 23(1):83-92. PubMed ID: 16492072
[TBL] [Abstract][Full Text] [Related]
20. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care.
Schäfer HH; Scheunert U
Swiss Med Wkly; 2013; 143():w13854. PubMed ID: 24163048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
